Immutep Limited Stock Australian S.E.
Stocks
IMMAQ
AU0000281537
Biotechnology & Medical Research
OTC Markets Traded| Market Cap | 70.74M 50.99M 43.88M 41.28M 37.71M 70.55M 4.81B 488M 189M 2.47B 191M 187M 7.96B | P/E 2027 * |
-2.4x | P/E 2028 * | -3.34x |
|---|---|---|---|---|---|
| Enterprise Value | 36.63M 26.4M 22.72M 21.38M 19.53M 36.53M 2.49B 253M 98.02M 1.28B 99.15M 96.98M 4.12B | EV / Sales 2027 * |
17.8x | EV / Sales 2028 * | 11.6x |
| Free-Float |
96.98% | Yield 2027 * |
-
| Yield 2028 * | - |
| Manager | Title | Age | Since |
|---|---|---|---|
Marc Voigt
CEO | Chief Executive Officer | 53 | 09/07/2014 |
David Fang
DFI | Director of Finance/CFO | - | 01/03/2018 |
Stephan Winckels
CTO | Chief Tech/Sci/R&D Officer | - | 01/07/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
Marc Voigt
BRD | Director/Board Member | 53 | 09/07/2014 |
Russell Howard
CHM | Chairman | 76 | 17/11/2017 |
Pete Meyers
BRD | Director/Board Member | 57 | 12/02/2014 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -.--% | -.--% | - | - | 49.84M | |
| -2.54% | -3.60% | -0.60% | +15.17% | 50.35B | |
| -0.40% | -5.03% | +428.09% | +499.20% | 45.2B | |
| -1.42% | +2.05% | +45.04% | +19.36% | 44.71B | |
| -1.22% | -3.82% | +6.54% | +71.48% | 41.24B | |
| +0.53% | -1.67% | +15.16% | +49.88% | 33.08B | |
| -0.21% | +8.50% | - | - | 17.81B | |
| -0.35% | -3.32% | +22.87% | +116.19% | 16.56B | |
| -1.01% | -0.38% | +15.69% | +28.39% | 14.82B | |
| -1.65% | -2.67% | +77.72% | +37.63% | 14B | |
| Average | -1.03% | +0.01% | +76.31% | +104.66% | 30.86B | |
| Weighted average by Cap. | -1.38% | -0.46% | +91.57% | +121.80% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 2.06M 1.48M 1.28M 1.2M 1.1M 2.05M 140M 14.18M 5.5M 71.81M 5.57M 5.45M 231M | 1.56M 1.12M 966K 908K 830K 1.55M 106M 10.73M 4.17M 54.35M 4.21M 4.12M 175M |
| Net income | -26.64M -19.2M -16.52M -15.55M -14.2M -26.57M -1.81B -184M -71.29M -930M -72.11M -70.54M -3B | -32.58M -23.49M -20.21M -19.01M -17.37M -32.49M -2.22B -225M -87.19M -1.14B -88.19M -86.27M -3.67B |
| Net Debt | -34.11M -24.59M -21.16M -19.91M -18.18M -34.02M -2.32B -235M -91.28M -1.19B -92.33M -90.31M -3.84B | -52.61M -37.92M -32.63M -30.7M -28.04M -52.46M -3.58B -363M -141M -1.84B -142M -139M -5.92B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
